TriangleNCT00602446 · STUDY IN CONTEXT
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Number of patients who discontinued deferasirox during 6 month daily treatment due to drug related toxicity
Efficacy as measured by reduction in liver iron concentration (LIC) after 6 months of the study drug compared to baseline (LIC at baseline minus LIC at 6 months). This shows the mean reduction for the 3 subjects treated in this study.
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-neuroblastoma
- nct id
- NCT00602446
- trial label
- Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
- applicability
- narrower
- applicability note
- Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 2
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-neuroblastoma
- nct id
- NCT00602446
- outcome key
- om-0000
- source section id
- NCT00602446-om-0000
- source outcome index
- 0
- endpoint
- Number of Patients Not Completing Treatment
- endpoint definition
- Number of patients who discontinued deferasirox during 6 month daily treatment due to drug related toxicity
- time origin
- 6 Months
- analysis role
- primary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- Note: 1 patient had a transient decrease in hemoglobin that required discontinuation of treatment for 2 weeks; subsequently restarted at same dose and completed therapy.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-neuroblastoma
- nct id
- NCT00602446
- outcome key
- om-0001
- source section id
- NCT00602446-om-0001
- source outcome index
- 1
- endpoint
- Reduction in Liver Iron Concentration After Study Drug
- endpoint definition
- Efficacy as measured by reduction in liver iron concentration (LIC) after 6 months of the study drug compared to baseline (LIC at baseline minus LIC at 6 months). This shows the mean reduction for the 3 subjects treated in this study.
- time origin
- 6 Months
- analysis role
- secondary
- reporting status
- POSTED
- data cutoff
- Source null
- population note
- All patients included in count.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-neuroblastoma
- nct id
- NCT00602446
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Deferasirox Treated
- regimen
- Includes patients that were treated with deferasirox for 6 months.
- analyzed count
- 3
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00602446-om-0000#groups/OG000
- release id
- clinical-indications-draft-1
- disease state id
- ds-neuroblastoma
- nct id
- NCT00602446
- outcome key
- om-0001
- arm key
- OG000
- arm label
- Deferasirox Treated
- regimen
- Includes patients that were treated with deferasirox for 6 months.
- analyzed count
- 3
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00602446-om-0001#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-neuroblastoma
- nct id
- NCT00602446
- harm key
- EG000
- source section id
- NCT00602446-ae
- event group key
- EG000
- event group label
- Deferasirox Treated
- serious affected
- 0
- serious at risk
- 3
- other affected
- 3
- other at risk
- 3
- frequency threshold
- 5
- collection period
- 6 Months
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice